



Customer No. 00270

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of) Group Art Unit: 1632
)
James M. Wilson et al) Examiner: R. Shukla
)
Appln No. 09/242,977)
)
Filed: February 26, 1999)
)
For: METHOD FOR RECOMBINANT) September 26, 2003
ADENO-ASSOCIATED VIRUS-)
DIRECTED GENE THERAPY)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE PURSUANT TO 37 CFR 1.111(a)

Sir:

This paper is in timely response to the Office Action dated March 27, 2003 issued in this application. A petition to extend the time for response for three months, from June 27, 2003 to September 27, 2003 is being filed herewith.

REMARKS

Claims 19-24, 26-28, and 30-38 are pending.

- I. Claims 19-24, 26-28 and 30-35 are rejected under 35 USC 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonable convey to one skilled in the art that the inventor(s), at the time the application was filed, had possession of rAAV "at least as free of the contaminating adenoviral helper virus as is obtained by subjecting said recombinant AAV to four rounds of cesium chloride gradient centrifugation."

Applicants respectfully traverse this rejection.